Several irAEs are late-onset [3C8], appearing after the confirmation of objective response, which might result in lower relativity. of irAEs and their correlations with objective response rate (ORR) in patients with advanced solid tumours treated with nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO+IPI). Methods PubMed, Embase and Cochrane library were Continue Reading